George Yancopoulos, co-founder and chief scientific officer of Regeneron Pharmaceuticals Inc (NASDAQ:REGN), has voiced concerns that the popular GLP-1s class of weight-loss drugs may lead to unintended health risks, particularly rapid muscle loss.
Yancopoulos warned that unless this side effect is mitigated, these treatments could ultimately cause “more harm than good.” Clinical studies indicate that patients using GLP-1s, such as Novo Nordisk A/S’ (NYSE:NVO) Ozempic and Wegovy, experience muscle loss much faster than those who lose weight through diet and exercise.
U.S. pharmacy claims data analysis reveals that only one in four patients prescribed Wegovy and Ozempic continue their treatment after two years.
In the Financial Times report, Yancopoulos emphasized that patients often regain ...
